[HTML][HTML] Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma

V Tchekmedyian, EJ Sherman, L Dunn… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
V Tchekmedyian, EJ Sherman, L Dunn, C Tran, S Baxi, N Katabi, CR Antonescu…
Journal of Clinical Oncology, 2019ncbi.nlm.nih.gov
PURPOSE Recurrent or metastatic adenoid cystic carcinoma (R/M ACC) is a malignant
neoplasm of predominantly salivary gland origin for which effective therapies are lacking.
We conducted a phase II trial evaluating the multitargeted tyrosine kinase inhibitor lenvatinib
in patients with R/M ACC.
Abstract
PURPOSE
Recurrent or metastatic adenoid cystic carcinoma (R/M ACC) is a malignant neoplasm of predominantly salivary gland origin for which effective therapies are lacking. We conducted a phase II trial evaluating the multitargeted tyrosine kinase inhibitor lenvatinib in patients with R/M ACC.
ncbi.nlm.nih.gov